Pieris Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de Pieris Pharmaceuticals' es Steve Yoder , nombrado en Dec 2014, tiene una permanencia de 9.33 años. compensación anual total es $2.06M, compuesta por 27.4% salario y 72.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.006% de las acciones de la empresa, por valor de €822.33. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 6.5 años, respectivamente.

Información clave

Steve Yoder

Chief Executive Officer (CEO)

US$1.4m

Compensación total

Porcentaje del salario del CEO	43.0%
Permanencia del CEO	9.4yrs
Participación del CEO	0.006%
Permanencia media de la dirección	4.6yrs
Promedio de permanencia en la Junta Directiva	6.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve Yoder en comparación con los beneficios de Pieris Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$1m	US$585k	-US$25m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$41m
Dec 31 2022	US$2m	US$565k	-US$33m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$42m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$2m	US$548k	-US$46m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$48m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$2m	US$535k	-US$37m
Sep 30 2020	n/a	n/a	-US$26m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$2m	US$515k	-US$28m
Sep 30 2019	n/a	n/a	-US$36m
Jun 30 2019	n/a	n/a	-US$40m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$3m	US$500k	-US$27m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$18m
Dec 31 2017	US$1m	US$450k	-US$18m

Compensación vs. Mercado: La compensación total de Steve($USD2.06M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD404.18K).

Compensación vs. Ingresos: La compensación de Steve ha sido consistente con los resultados de la empresa en el último año.

CEO

Steve Yoder (47 yo)

9.4yrs

Permanencia

US$1,358,952

Compensación

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen Yoder	CEO, President & Director	9.4yrs	US$1.36m	0.0061% $ 775.6
Thomas Bures	Senior VP	4.7yrs	US$729.04k	0.019% $ 2.5k
Shane Olwill	Senior VP & Chief Development Officer	no data	US$705.45k	sin datos
Maria Kelman	Executive Director of Investor Relations	no data	sin datos	sin datos
Prompong Chaikul	Chief Supply Chain Officer	4.6yrs	sin datos	sin datos
Florian Witte	VP and Head of Alliance Management & Early Project Leadership	1.3yrs	sin datos	sin datos

4.6yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PI6 se considera experimentado (4.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen Yoder	CEO, President & Director	9.4yrs	US$1.36m	0.0061% $ 775.6
James Arthur Geraghty	Independent Chairman	7yrs	US$94.09k	0.020% $ 2.6k
Michael Richman	Independent Director	9.4yrs	US$52.09k	0% $ 0
Christopher Kiritsy	Independent Director	7.7yrs	US$72.58k	0.020% $ 2.6k
Peter Kiener	Independent Director	5.7yrs	US$65.08k	0% $ 0
Matthew Sherman	Independent Director	5.6yrs	US$53.09k	0% $ 0
Ann Barbier	Independent Director	6.1yrs	US$52.09k	0% $ 0
Maya Said	Independent Director	4.8yrs	US$52.09k	0% $ 0
Ian Adcock	Member of Clinical & Scientific Advisory Board	no data	sin datos	sin datos
Oliver Eickelberg	Member of Clinical & Scientific Advisory Board	no data	sin datos	sin datos
Fan Chung	Member of Clinical & Scientific Advisory Board	no data	sin datos	sin datos
Peter Barnes	Member of Clinical & Scientific Advisory Board	no data	sin datos	sin datos

6.5yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de PI6 se considera experimentada (6.5 años de antigüedad promedio).

Pieris Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Executive Changes

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Recent updates

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.13 loss in 3Q 2022)

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Executive Changes

New major risk - Financial position

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)

Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)

Insufficient new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.24 loss in 3Q 2021)

Pieris Pharmaceuticals, Inc. Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.25 loss in 2Q 2021)

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

First quarter 2022 earnings released: US$0.069 loss per share (vs US$0.074 loss in 1Q 2021)

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2A Trial of PRS-060/AZD1402

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)

Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index

First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)

Pieris Pharmaceuticals, Inc. announced that it expects to receive $10.000002 million in funding from AstraZeneca PLC

Pieris Pharmaceuticals, Inc. announced that it has received $13.008671 million in funding

New 90-day low: €1.99

New 90-day high: €2.47

Third quarter 2020 earnings released: US$0.26 loss per share

Revenue misses expectations

New 90-day low: €1.94

Earnings released

New 90-day low - €2.16

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad